Posts by Sandra Ansanay-Alex
Apertus: A New Opportunity for Swiss Health Valley and Healthcare Innovation
Created through a collaboration between EPFL, ETH Zurich, and the Swiss National Supercomputing Centre (CSCS), Apertus is more than just a technical achievement. It represents a strategic opportunity for the Swiss Health Valley, offering a trusted, transparent, and sovereign foundation for the integration of AI in life sciences and healthcare. A Truly Open AI…
Read MoreHevelion, IRIS and Kymansis awarded by the FIT
The Fondation pour l’Innovation Technologique awards three life sciences projects from CHUV and EPFL: Hevelion from UNIL-CHUV, and IRIS and Kymansis from EPFL. They received CHF 100’000 Tech Grants to continue developing their technologies. Hevelion: spatial omics for new targeted therapies Hevelion is developing an AI-powered software platform to accelerate spatial biomarker discovery for…
Read MoreAntoine Geissbühler, President of BioAlps, Receives Prestigious International Award
BioAlps is proud to celebrate its President, Professor Antoine Geissbühler, who has been awarded the François Grémy Award of Excellence by the International Medical Informatics Association (IMIA). This distinction, granted every two years, honors leaders who have made outstanding contributions to the field of medical informatics worldwide. Professor Antoine Geissbühler shares this year’s honor…
Read MoreWho You Inherit From Matters: New Genetic Study Uncovers Parent-Specific Effects
A groundbreaking study led by the SIB Statistical Genetics Group (University of Lausanne and Unisanté) reveals that the same genetic variant can affect traits like height, metabolism, and disease risk differently depending on whether it’s inherited from the mother or father. Using a new computational method, researchers analyzed DNA from over 236,000 individuals across…
Read MoreSNSF – Starting Grant
Apply before from 1 February until 5 May 2026 for the Swiss National Science Foundation Starting Grant SNSF Starting Grants 2025 represent the SNSF’s highest level of career funding. The call enables researchers to carry out their own independent project and lead a research team in Switzerland. Applicants must have several years of research…
Read MoreThe Origin of Astrocytes Revealed
A major discovery in neuroscience: a study from the Faculty of Medicine (FacMed) and the Synapsy Center at the University of Geneva uncovers that cortical astrocytes originate from two distinct progenitor cell types. Long considered a uniform support cell population, astrocytes are now recognized as diverse and essential players in brain function, involved in…
Read MoreNovochizol’s AgrINovo Partnership: Swiss-Indian Alliance for Agricultural Innovation
Indian company Aquagri, its partner, and Novochizol SA, a Valais-based startup, announced the launch of AgrINovo, a transformative collaborative project. AgrINovo aims to unlock the full potential of Novochizol technology to foster a healthier, more sustainable agriculture in India and worldwide. Novochizol™ is derived from chitosan, made from chitin, the second most abundant polysaccharide…
Read MoreSwiss Health Valley Biotechs Advance Drug Pipelines with Promising Clinical Milestones
Three innovative biotech companies based in Western Switzerland, Stalicla, Legacy Healthcare and iOnctura, have recently achieved significant progress in their therapeutic pipelines, reinforcing the region’s position as a hub for health innovation. STALICLA: Advancing Precision Medicine for Autism Geneva-based STALICLA has received the green light from the U.S. Food and Drug Administration (FDA) to initiate…
Read MoreRelief Therapeutics is preparing a reverse merger with NeuroX, the successor to MindMaze
The merger must take the form of an exchange of all NeuroX shares for newly issued shares in Relief. The transaction, which is expected to be finalised before the end of the year, would value the Geneva-based company at CHF 100 million and its future partner at CHF 1 billion. The Geneva-based pharmaceutical company…
Read MoreAzureCell Therapies and Myriad Optics Awarded by Gebert Rüf Stiftung Innobooster Programme
Two Swiss Health Valley projects, from EPFL and University of Geneva, got a CHF 150’000 Innobooster grant from Gebert Rüf Stiftung programme: AzureCell Therapies and Myriad Optics. AzureCell Therapies | Bilal Fares, University of Geneva Every 9 min, a new patient is diagnosed with Parkinson’s, a condition long considered incurable due to the irreversible loss…
Read More